LRRK2 and Parkinson disease: As for LRRK2, GCase activity is altered in subjects with PD and significantly reduced in both iPD and GBA-PD monocytes compared to HCs (Atashrazm et al., 2018; Hughes et al., 2021), suggesting that GCase dysfunction in immune cells may also be a biomarker of early PD and important in its pathophysiology.